A month after GlaxoSmithKline sold all of its rights to Entereg® (alvimopan) back to Adolor, Cubist Pharmaceuticals has agreed to acquire Adolor for a potential consideration of US$415 M. With the acquisition, Cubist will also gain Adolor’s lead development programme ADL5945, which is scheduled to begin Phase III development for chronic opioid-induced constipation in 2012. Of the total transaction value, US$225 M is contingent upon the regulatory success of the drug candidate. Cubist will leverage its existing hospital-based sales force to promote Entereg.